Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Human α2-Macroglobulin: Architecture, Mechanisms, and Functional Implications.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2026
Same author

Expression, Solubilization, and Refolding Recovery of a Novel l‑Asparaginase-Arginase 1 Chimera from <i>E. coli</i> Inclusion Bodies.

ACS omega·2026
Same author

Tailored high-cell-density fed-batch cultivation and induction strategies for optimized production of a low-immunogenic L-asparaginase mutant in Escherichia coli.

Enzyme and microbial technology·2026
Same author

Toward Safer Biotherapeutics: Expression and Characterization of a Humanized Chimeric L-Asparaginase in <i>E. coli</i>.

International journal of molecular sciences·2025
Same author

An efficient and reliable determination of hyaluronidase supports revision of the United States Pharmacopeia USP46-NF41 monograph - Hyaluronidase for injection.

Journal of pharmaceutical and biomedical analysis·2025
Same author

Microbial astaxanthin-encapsulated polymeric micelles from yeast Phaffia rhodozyma for personalized bioactive colored natural rubber latex bandages.

International journal of biological macromolecules·2025

Related Experiment Video

Updated: Jan 8, 2026

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes
13:53

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes

Published on: December 19, 2020

5.3K

Asparaginase with Combined Mutations: Optimized Biochemistry and Lowered Allergic Risk.

Tales Costa-Silva1,2, Grace V Ruiz-Lara2, Iris Munhoz Costa2

  • 1Center for Natural and Human Sciences, Federal University of ABC, Santo André, São Paulo 09210580, Brazil.

ACS Pharmacology & Translational Science
|December 18, 2025
PubMed
Summary
This summary is machine-generated.

Engineered a novel asparaginase biobetter with enhanced stability and reduced immunogenicity for improved leukemia treatment. This optimized enzyme offers a promising next-generation biopharmaceutical alternative.

Keywords:
ALL-molecular biologyALL-molecular diagnosis and therapyallergyasparaginasebiobetterbiologics

More Related Videos

Engineering Chimeric Antigen Receptor-Natural Killer Cells Targeting Fungal Infections Using the Non-viral Sleeping Beauty Transposon System
08:29

Engineering Chimeric Antigen Receptor-Natural Killer Cells Targeting Fungal Infections Using the Non-viral Sleeping Beauty Transposon System

Published on: October 4, 2024

1.2K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.2K

Related Experiment Videos

Last Updated: Jan 8, 2026

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes
13:53

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes

Published on: December 19, 2020

5.3K
Engineering Chimeric Antigen Receptor-Natural Killer Cells Targeting Fungal Infections Using the Non-viral Sleeping Beauty Transposon System
08:29

Engineering Chimeric Antigen Receptor-Natural Killer Cells Targeting Fungal Infections Using the Non-viral Sleeping Beauty Transposon System

Published on: October 4, 2024

1.2K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.2K

Area of Science:

  • Biotechnology and Biomedical Engineering
  • Enzymology
  • Immunology

Background:

  • Native Escherichia coli asparaginase is a critical biologic for leukemia treatment but requires optimization.
  • Existing native asparaginase faces challenges including limited thermostability, short half-life, protease susceptibility, and allergenicity.

Purpose of the Study:

  • To engineer a novel antileukemic asparaginase biobetter with improved biochemical and immunological properties.
  • To evaluate the biochemical characteristics, cytotoxicity, and in vivo safety and efficacy of the engineered asparaginase.

Main Methods:

  • Site-directed mutagenesis was used to introduce specific amino acid substitutions (P40S/S206C/N24S) into Escherichia coli asparaginase.
  • Biochemical characterization included enzyme kinetics, thermostability, and proteolytic resistance assays.
  • Cytotoxicity was assessed against leukemic cell lines, and immunogenicity was evaluated in Balb/c SPF mice.

Main Results:

  • The triple mutant (TM) exhibited robust asparaginase activity with a >3-fold lower KM for asparagine.
  • TM demonstrated superior thermostability, enhanced proteolytic resistance, and a lower in silico immunogenicity score compared to wild-type.
  • In vivo studies showed TM had no apparent toxicity, reduced platelet count reduction, and lower induction of anti-asparaginase IgE antibodies.

Conclusions:

  • The engineered triple mutant asparaginase offers substantial biochemical and immunological improvements over the wild-type enzyme.
  • Targeted amino acid substitutions represent a viable strategy for advancing next-generation asparaginase biopharmaceuticals.
  • This biobetter holds potential for improved efficacy and safety in leukemia therapy.